Stryker (NYSE:SYK) Price Target Increased to $380.00 by Analysts at Evercore ISI

Stryker (NYSE:SYK) had its target price boosted by investment analysts at Evercore ISI from $365.00 to $380.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical technology company’s stock. Evercore ISI’s price target would suggest a potential upside of 6.23% from the stock’s current price.

SYK has been the subject of several other research reports. Barclays boosted their price target on Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Truist Financial lowered their price target on Stryker from $364.00 to $345.00 and set a “hold” rating for the company in a research note on Thursday, August 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $386.00 price target on shares of Stryker in a research note on Wednesday, July 31st. BTIG Research boosted their target price on Stryker from $360.00 to $374.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a report on Monday, September 16th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $379.37.

Stryker Stock Down 1.0 %

NYSE:SYK traded down $3.55 on Tuesday, hitting $357.71. 294,165 shares of the company’s stock traded hands, compared to its average volume of 1,275,802. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. Stryker has a 1 year low of $249.98 and a 1 year high of $374.63. The firm has a 50-day moving average price of $348.29 and a 200-day moving average price of $343.00. The company has a market cap of $136.27 billion, a PE ratio of 40.82, a price-to-earnings-growth ratio of 2.78 and a beta of 0.91.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.02. The company had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.54 EPS. Equities analysts anticipate that Stryker will post 12 EPS for the current fiscal year.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at $3,715,540. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now owns 2,852 shares of the company’s stock, valued at $949,716. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 220,068 shares of company stock valued at $71,811,372. 5.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stryker

Hedge funds have recently modified their holdings of the business. Centennial Bank AR raised its position in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the period. Central Pacific Bank Trust Division bought a new position in shares of Stryker during the first quarter worth about $39,000. Accent Capital Management LLC bought a new position in shares of Stryker during the fourth quarter worth about $60,000. Sachetta LLC grew its holdings in shares of Stryker by 16.3% during the second quarter. Sachetta LLC now owns 242 shares of the medical technology company’s stock worth $80,000 after buying an additional 34 shares in the last quarter. Finally, Hazlett Burt & Watson Inc. grew its holdings in shares of Stryker by 17.9% during the first quarter. Hazlett Burt & Watson Inc. now owns 264 shares of the medical technology company’s stock worth $94,000 after buying an additional 40 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.